Activators of nuclear factor-erythroid 2-related factor 2 (NRF2) could lead to promising therapeutics for prevention and treatment of oxidative stress and inflammatory disorders. Ubiquitination and ...

GlobalData’s report assesses the drugs in the Nuclear Factor Erythroid 2 Related Factor 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development ...

Researchers have identified a possible new targeted drug for treating acute myeloid leukemia. In the future, the discovery may help patients with certain rare subtypes of the disease.

The lab uses biochemical and cell biology techniques to monitor the expression and interactions of erythroid specific proteins throughout differentiation in health and disease.

Erythroid maturation-dependent remodelling of CTLH E3 complex, along with its cognate E2, controls the orderly progression of human erythropoiesis, thus establishing a paradigm for other E2-E3 ...

Erythroleukemia is a cancer of the blood and bone marrow. It’s a rare subtype of acute myeloid leukemia (AML) and is sometimes called acute erythroid leukemia or M6-AML. Erythroleukemia occurs ...

Red blood cells are produced by terminal erythroid differentiation, which involves the dramatic morphological transformation of erythroblasts into enucleated reticulocytes. Microtubules are important ...

However, how dietary restriction impacts erythroid system is largely unknown. We found that a short-term caloric restriction (CR) stimulates expression of KLF1, a master regulator of erythroid ...